GRANTS / FUNDING
Preclinical & Phase 1
WP1234 has benefitted from nearly $2 million in grants and approximately $1 million in development dollars invested in furthering the technology and is expected to receive over $2 million in the next 24 months for preclinical testing and Phase I clinical trials.
DRUG DISCOVERY & DEVELOPMENT
Leading cancer research center in the world, drug discovery.
Moleculin Biotech, Inc.
ALS through its development partner will be performing the preclinical work necessary to evaluate WP1234 as a potential treatment for pancreatic cancer.
Pancreatic cancer. Promising treatment combination can include radiotherapy. Brain and liver metastatic tumors. Because existing cancer treatments (including radiation) can often result in highly glycolytic phenotypes (surviving cancer cells that are particularly dependent upon glycolysis, a specific metabolism of glucose), we believe WP1234 could be useful in combination with existing therapies in a wide range of cancers.
In addition, highly glycolytic tumor cell lines are more resistant to classical chemotherapeutics thus a combination of WP1234 with cytotoxic agents should produce significantly enhanced anticancer effects. We have demonstrated such effects using inhibitors of glycolysis and cytotoxic drugs using in vivo human tumor models.